問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
張義芳
下載
2018-05-01 - 2022-12-31
Condition/Disease
Test Drug
Participate Sites3Sites
Not yet recruiting1Sites
Recruiting2Sites
2021-09-01 - 2025-03-31
Participate Sites5Sites
Recruiting4Sites
Terminated1Sites
2021-06-01 - 2026-02-01
Participate Sites6Sites
Recruiting6Sites
2019-10-01 - 2046-12-31
Participate Sites12Sites
Recruiting12Sites
2020-01-06 - 2026-01-31
Recruiting5Sites
2020-08-17 - 2023-12-12
2022-05-02 - 2023-04-18
2023-04-01 - 2026-12-31
Participate Sites7Sites
2019-04-01 - 2027-04-24
Participate Sites10Sites
Recruiting10Sites
2018-09-01 - 2022-12-31
Hepatocellular Carcinoma (HCC)
nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞
Participate Sites9Sites
Recruiting8Sites
全部
